{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:59:19Z","timestamp":1780905559416,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd011831","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T00:00:00Z","timestamp":1506124800000}}],"reference-count":60,"publisher":"Wiley","issue":"9","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd011831.pub2","type":"journal-article","created":{"date-parts":[[2017,9,23]],"date-time":"2017-09-23T04:10:53Z","timestamp":1506139853000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Chlorpromazine versus penfluridol for schizophrenia"],"prefix":"10.1002","volume":"2017","author":[{"given":"Naemeh","family":"Nikvarz","sequence":"first","affiliation":[{"name":"Kerman University of Medical Sciences; Herbal and Traditional Medicines Research Center, Faculty of Pharmacy and Pharmaceutical Sciences; Haft Bagh Square Kerman Iran 7616911319"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa","family":"Vahedian","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Department of Biostatistics and Epidemiology; Haft Bagh Street Block C Kerman Iran 7616911317"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navid","family":"Khalili","sequence":"additional","affiliation":[{"name":"Kerman University of Medical Sciences; Department of Psychiatry; Shahid Beheshti Hospital Jomhuri Eslami Blvd Kerman Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2017,9,23]]},"reference":[{"issue":"7","key":"10.1002\/14651858.CD011831.pub2-BIB0003|cit1","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1176\/ajp.133.7.850","article-title":"Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit","volume":"133","author":"Chouinard","year":"1976","journal-title":"American Journal of Psychiatry"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0001|cit2","first-page":"325","article-title":"Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic","volume":"1","author":"Chouinard","year":"1977","journal-title":"Communications in Psychopharmacology"},{"issue":"2-3","key":"10.1002\/14651858.CD011831.pub2-BIB0002|cit3","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/j.1552-4604.1977.tb04602.x","article-title":"Penfluridol in the maintenance treatment of schizophrenic patients newly discharged from a brief therapy unit","volume":"17","author":"Chouinard","year":"1977","journal-title":"Journal of Clinical Pharmacology"},{"issue":"2","key":"10.1002\/14651858.CD011831.pub2-BIB0004|cit4","first-page":"107","article-title":"Penfluridol: a long acting oral antipsychotic drug","volume":"40","author":"Claghorn","year":"1979","journal-title":"Journal of Clinical Psychiatry"},{"issue":"5-6","key":"10.1002\/14651858.CD011831.pub2-BIB0005|cit5","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1002\/j.1552-4604.1982.tb02667.x","article-title":"Study of penfluridol and chlorpromazine in the treatment of chronic schizophrenia","volume":"22","author":"Wang","year":"1982","journal-title":"Journal of Clinical Pharmacology"},{"issue":"5","key":"10.1002\/14651858.CD011831.pub2-BIB0006|cit6","first-page":"274-6, 318","article-title":"A double-blind study on the effect of clozapine, penfluridol and chlorpromazine in the treatment of schizophrenia","volume":"21","author":"Bao","year":"1988","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"issue":"6","key":"10.1002\/14651858.CD011831.pub2-BIB0007|cit7","first-page":"325","article-title":"Application of NOSIE in the study of neuroleptic treatment","volume":"20","author":"Li","year":"1987","journal-title":"Chinese Journal of Neurology and Psychiatry"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/1741-7015-3-15","article-title":"Chlorpromazine for schizophrenia: a Cochrane systematic review of 50 years of randomised controlled trials","volume":"3","author":"Adams","year":"2005","journal-title":"BMC Medicine"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0009|cit9","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD000284.pub3","article-title":"Chlorpromazine versus placebo for schizophrenia","author":"Adams","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0010|cit10","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007445.pub2","article-title":"Chlorpromazine for psychosis induced aggression or agitation","author":"Ahmed","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD011831.pub2-BIB0011|cit11","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1192\/bjp.171.6.524","article-title":"Brazilian multicentric study of psychiatric morbidity. Methodological features and prevalence estimates","volume":"171","author":"Almeida-Filho","year":"1997","journal-title":"British Journal of Psychiatry"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0012|cit12","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD006329","article-title":"Cessation of medication for people with schizophrenia already stable on chlorpromazine","author":"Almerie","year":"2007","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7066","key":"10.1002\/14651858.CD011831.pub2-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/bmj.313.7066.1200","article-title":"Detecting skewness from summary information","volume":"313","author":"Altman","year":"1996","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0014|cit14","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011662","article-title":"Acetophenazine versus chlorpromazine for schizophrenia","author":"Bazrafshan","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0015|cit15","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1136\/bmj.315.7108.600","article-title":"Statistics notes. Trials randomised in clusters","volume":"315","author":"Bland","year":"1997","journal-title":"BMJ"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0016|cit16","first-page":"405","article-title":"The problem of therapeutic efficacy indices. 3. Comparison of the indices and their use","volume":"54","author":"Boissel","year":"1999","journal-title":"Therapie"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0017|cit17","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1943-278X.1992.tb01040.x","article-title":"Schizophrenia--a high-risk factor for suicide: clues to risk reduction","volume":"22","author":"Caldwell","year":"1992","journal-title":"Suicide and Life-Threatening Behavior"},{"issue":"6207","key":"10.1002\/14651858.CD011831.pub2-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1136\/bmj.280.6207.66","article-title":"Molecular pathology of schizophrenia: more than one disease process?","volume":"280","author":"Crow","year":"1980","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0019|cit19","unstructured":"Deeks J Issues in the selection for meta-analyses of binary data 8th International Cochrane Colloquium; 2000 Oct 25-28; Cape Town Cape Town The Cochrane Collaboration 2000"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0020|cit20","unstructured":"Deeks JJ Higgins JPT Altman DG editor(s) Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"6","key":"10.1002\/14651858.CD011831.pub2-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1007\/BF02599201","article-title":"The unit of analysis error in studies about physicians' patient care behavior","volume":"7","author":"Divine","year":"1992","journal-title":"Journal of General Internal Medicine"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1002\/sim.1301","article-title":"Issues in the meta-analysis of cluster randomized trials","volume":"21","author":"Donner","year":"2002","journal-title":"Statistics in Medicine"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0023|cit23","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD007778.pub2","article-title":"Chlorpromazine dose for people with schizophrenia","author":"Dudley","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0024|cit24","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","article-title":"Bias in meta-analysis detected by a simple, graphical test","volume":"315","author":"Egger","year":"1997","journal-title":"BMJ"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0025|cit25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/ije\/31.1.140","article-title":"Meta-analyses involving cross-over trials: methodological issues","volume":"31","author":"Elbourne","year":"2002","journal-title":"International Journal of Epidemiology"},{"issue":"6","key":"10.1002\/14651858.CD011831.pub2-BIB0026|cit26","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011709","article-title":"Chlorpromazine versus piperacetazine for schizophrenia","author":"Eslami Shahrbabaki","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"2","key":"10.1002\/14651858.CD011831.pub2-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s11065-005-6254-9","article-title":"A meta-analysis of cognitive deficits in adults with a diagnosis of schizophrenia","volume":"15","author":"Fioravanti","year":"2005","journal-title":"Neuropsychology Review"},{"issue":"7","key":"10.1002\/14651858.CD011831.pub2-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","article-title":"Imputing missing standard deviations in meta-analyses can provide accurate results","volume":"59","author":"Furukawa","year":"2006","journal-title":"Journal of Clinical Epidemiology"},{"issue":"2","key":"10.1002\/14651858.CD011831.pub2-BIB0029|cit29","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1600-0447.1975.tb00029.x","article-title":"Peroral and parenteral administration of long-acting neuroleptics: a double-blind study of penfluridol compared to flupenthixol decanoate in the treatment of schizophrenia","volume":"52","author":"Gerlach","year":"1975","journal-title":"Acta Psychiatrica Scandinavica"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0030|cit30","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1093\/oxfordjournals.aje.a009904","article-title":"Components of variance and intraclass correlations for the design of community-based surveys and intervention studies: data from the Health Survey for England 1994","volume":"149","author":"Gulliford","year":"1999","journal-title":"American Journal of Epidemiology"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0031|cit31","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0032|cit32","unstructured":"Higgins JPT Green S editor(s) Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S, editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0033|cit33","unstructured":"Higgins JPT Altman DG Sterne JAC editor(s) Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1365-2141.2009.07707.x","article-title":"Number needed to treat and number needed to harm are not the best way to report and assess the results of randomised clinical trials","volume":"146","author":"Hutton","year":"2009","journal-title":"British Journal of Haematology"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0035|cit35","first-page":"33","article-title":"Penfluridol in the maintenance therapy of schizophrenia","volume":"21","author":"Ionescu","year":"1983","journal-title":"Neurologie et Psychiatrie"},{"issue":"2","key":"10.1002\/14651858.CD011831.pub2-BIB0036|cit36","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0014-2999(70)90043-9","article-title":"The pharmacology of penfluridol (R 16341) a new potent and orally long-acting neuroleptic drug","volume":"11","author":"Janssen","year":"1970","journal-title":"European Journal of Pharmacology"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0037|cit37","volume-title":"Positive and Negative Syndrome Scale (PANSS) Manual","author":"Kay","year":"1986"},{"issue":"11","key":"10.1002\/14651858.CD011831.pub2-BIB0038|cit38","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","article-title":"Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology","volume":"59","author":"Leon","year":"2006","journal-title":"Biological Psychiatry"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0039|cit39","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1192\/bjp.187.4.366","article-title":"Clinical implications of brief psychiatric rating scale scores","volume":"187","author":"Leucht","year":"2005","journal-title":"British Journal of Psychiatry"},{"issue":"2-3","key":"10.1002\/14651858.CD011831.pub2-BIB0040|cit40","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophrenia Research"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0041|cit41","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD004278.pub2","article-title":"Haloperidol versus chlorpromazine for schizophrenia","author":"Leucht","year":"2008","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1192\/bjp.151.2.145","article-title":"The symptoms of chronic schizophrenia. A re-examination of the positive-negative dichotomy","volume":"151","author":"Liddle","year":"1987","journal-title":"British Journal of Psychiatry"},{"issue":"2","key":"10.1002\/14651858.CD011831.pub2-BIB0043|cit43","doi-asserted-by":"crossref","first-page":"106","DOI":"10.2165\/00019053-200018020-00002","article-title":"Patient compliance with drug therapy in schizophrenia. Economic and clinical issues","volume":"18","author":"Lindstrom","year":"2000","journal-title":"PharmacoEconomics"},{"issue":"7","key":"10.1002\/14651858.CD011831.pub2-BIB0044|cit44","doi-asserted-by":"crossref","first-page":"936","DOI":"10.4088\/JCP.10m06244gry","article-title":"Sudden deaths in psychiatric patients","volume":"72","author":"Manu","year":"2011","journal-title":"Journal of Clinical Psychiatry"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1192\/bjp.176.3.249","article-title":"Unpublished rating scales: a major source of bias in randomised controlled trials of treatments for schizophrenia","volume":"176","author":"Marshall","year":"2000","journal-title":"British Journal of Psychiatry"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0046|cit46","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1471-2288-1-2","article-title":"The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials","volume":"1","author":"Moher","year":"2001","journal-title":"BMC Medical Research Methodology"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0047|cit47","doi-asserted-by":"crossref","first-page":"799","DOI":"10.2466\/pr0.1962.10.3.799","article-title":"The brief psychiatric rating scale","volume":"10","author":"Overall","year":"1962","journal-title":"Psychological Reports"},{"issue":"1","key":"10.1002\/14651858.CD011831.pub2-BIB0048|cit48","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1001\/archpsyc.64.1.19","article-title":"Lifetime prevalence of psychotic and bipolar I disorders in a general population","volume":"64","author":"Perala","year":"2007","journal-title":"Archives of General Psychiatry"},{"issue":"5197","key":"10.1002\/14651858.CD011831.pub2-BIB0049|cit49","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1136\/bmj.2.5197.522","article-title":"Chlorpromazine and allied phenothiazine derivatives","volume":"2","author":"Rees","year":"1960","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0050|cit50","first-page":"1550","article-title":"Penfluridol","volume-title":"Martindale: The Extra Pharmacopoeia","author":"Reynolds","year":"1982"},{"issue":"4","key":"10.1002\/14651858.CD011831.pub2-BIB0051|cit51","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010631.pub2","article-title":"Chlorpromazine versus atypical antipsychotic drugs for schizophrenia","author":"Saha","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0052|cit52","unstructured":"Sch\u00fcnemann HJ Oxman AD Vist GE Higgins JPT Deeks JJ Glasziou P Chapter 12: Interpreting results and drawing conclusions. In Higgins JPT, Green S editor(s), Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"issue":"2","key":"10.1002\/14651858.CD011831.pub2-BIB0053|cit53","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD002923.pub2","article-title":"Penfluridol for schizophrenia","author":"Soares","year":"2006","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0054|cit54","unstructured":"Sterne JAC Egger M Moher D editor(s) Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Intervention. Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011 Available from www.handbook.cochrane.org"},{"issue":"5","key":"10.1002\/14651858.CD011831.pub2-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta3050","article-title":"Methods for evaluating area-wide and organisation-based intervention in health and health care: a systematic review","volume":"3","author":"Ukoumunne","year":"1999","journal-title":"Health Technology Assessment"},{"issue":"5789","key":"10.1002\/14651858.CD011831.pub2-BIB0056|cit56","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1136\/bmj.4.5789.710","article-title":"Controlled trial of penfluridol in acute psychosis","volume":"4","author":"Praag","year":"1971","journal-title":"British Medical Journal"},{"key":"10.1002\/14651858.CD011831.pub2-BIB0057|cit57","unstructured":"World Health Organization 19th WHO Essential Medicines List www.who.int\/medicines\/publications\/essentialmedicines\/en\/"},{"issue":"7","key":"10.1002\/14651858.CD011831.pub2-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1192\/pb.bp.108.021949","article-title":"Loss to outcomes stakeholder survey: the LOSS study","volume":"33","author":"Xia","year":"2009","journal-title":"Psychiatric Bulletin"},{"issue":"3","key":"10.1002\/14651858.CD011831.pub2-BIB0059|cit59","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011655.pub2","article-title":"Chlorpromazine versus metiapine for schizophrenia","author":"Zare","year":"2017","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD011831.pub2-BIB0060|cit60","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011831","article-title":"Chlorpromazine versus penfluridol for schizophrenia","author":"Khalili","year":"2015","journal-title":"Cochrane Database of Systematic Reviews"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD011831.pub2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T07:34:14Z","timestamp":1780904054000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD011831.pub2"}},"subtitle":[],"editor":[{"name":"Cochrane Schizophrenia Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2017,9,23]]},"references-count":60,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2017,9]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd011831.pub2","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,23]]}}}